Loading...

4,068 posters, 219 videos, 101 topics, 69 sessions, 14,365 authors, 6,128 institutions

ePostersLive by SciGen Technologies S.A. All rights reserved.

Alzheimer's Association International Conference 2026

July 12-15, 2026 | London, United Kingdom, and Online

Alzheimer's Association International Conference 2026 banner

9311

Identification Of Transcriptional Regulators Of Specific Microglial States In Alzheimer’S Disease Using Single-nucleus Multi-omic Data

Part of Topic

Background & Motivation


  • Alzheimer's disease (AD) is the most common cause of dementia, affecting tens of millions worldwide, yet no disease-modifying treatment exists

  • Microglia, the brain's resident immune cells, play a central role in AD by clearing amyloid plaques and regulating neuroinflammation

  • Single-nucleus RNA sequencing (snRNA-seq) has revealed that microglia are not a single uniform population; they adopt distinct functional substates in disease

  • Two such substate, MG4 and MG8, have been identified as being selectively enriched in AD and is characterized by upregulation of lipid-processing and inflammatory programs respectively

Key Findings

  • Microglial states from the Sun et al. (2023) atlas transferred onto both cohorts (GSE174367, GSE214979); MG0 (the homeostatic cluster) was the most abundant state in most donors, with substantial donor-to-donor variation across the remaining states and no clean AD-versus-control compositional shift obvious from composition alone (Fig. 1).

  • Upon successful label integration, MG8 often fell below statistically analyzable threshold (<10 cells / donor), whereas MG4 is relatively more abundant

  • TF regulon activity was strongly context-dependent. Most regulons changed only in specific states, specific disease contrasts, or a single dataset rather than showing uniform AD-versus-control shifts, which is why a single aggregated contrast would have missed them (Fig. 3).

  • A reproducibility-based analysis recovered regulators already linked to AD microglia (NFATC1, FOXP1, MEF2A/MEF2C) alongside less-characterized candidates that reproduced within (E2F6, ZNF217) and across (BATF, KLF3, ZEB2) cohorts (Fig. 2, Sets 1-2).

  • Three TFs showed concordant direction in transcriptional activity and AD-associated chromatin accessibility: BACH2 and ZBTB7A (positive), RUNX3 (negative), giving preliminary cross-layer support for a small subset of candidates (Fig. 2, Set 3).

Figure 1: MG4 Distribution & Enrichment

  • Per-donor stacked bar charts of microglial state assignments (MG0-MG12, excluding cluster 9 which is macrophage) in GSE214979 (Anderson et al. 2023; left, AD vs. control) and GSE174367 (Morabito et al. 2021; right, AD vs. control), transferred from Sun et al (2023) reference; combined bar height is the total number of microglia present in a donor.

Figure 2: TF Sets Definition

  • (A) Venn diagrams defining three reproducibility tiers. Set 1, within-cohort reproducibility in GSE214979 and GSE174367. Set 2, cross-cohort reproducibility (Morabito vs. Anderson) for four matched contrasts. Set 3, overlap between snRNA differential regulon activity and AD-enriched snATAC accessibility. 

  • (B) Member TFs per set with the two source contrasts, set assignment, and effect direction (sign). 

Figure 3: TF Activity Enrichment

  • Heatmap of regulon activity (normalized enrichment score, NES) inferred with msVIPER using DoRothEA regulons. Rows are TFs enriched in at least one contrast; columns are eight contrasts spanning the two cohorts (NEW = GSE214979, OLD = GSE174367), defined by disease (AD vs. control, in all microglia or restricted to MG4) and by state (MG4 vs. rest, MG8 vs. rest). Red indicates higher and blue lower regulon activity; asterisks mark p-value < 0.05.

Acknowledgements

  • This work is supported in part by NIH R01 AG071470, U01 AG066833, U01 AG068057, and U19 AG074879. 



Comments

Email is required but is not shown publicly.

Loading comments...

aaic2026 banner
Copyright © 2015-2026, ePostersLive® SciGen is a registered trademark of SciGen Technologies S.A. Patent pending.

This website and third-party tools we use rely on cookies for the best user experience. By selecting "I agree", you agree to cookie usage as described in our Privacy Policy.